Market News

Syros Pharma Acquires Acute Promyelocytic Leukemia Drug; Street Firmly Bullish

Syros Pharmaceuticals announced the acquisition of a clinical-stage drug candidate for Acute Promyelocytic Leukemia (or APL) from Orsenix, LLC.

Syros (SYRS) has acquired from Orsenix all of the assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide. Under the terms of the asset purchase agreement, Syros has made an upfront cash payment of $12 million to Orsenix.

Additionally, Orsenix is eligible to receive a $6 million regulatory milestone related to the development of SY-2101 in APL and commercial milestones of up to $10 million. Orsenix could also receive single-digit million dollar milestone payments related to the development of SY-2101 in indications other than APL. (See SYRS stock analysis on TipRanks)

As per Syros, “SY-2101 represents a strategic opportunity to leverage Syros’ expertise and capabilities to advance its growing footprint in hematologic disorders, with a targeted clinical-stage drug candidate that has the potential to dramatically reduce the treatment burden of a standard-of-care regimen for newly diagnosed acute promyelocytic leukemia (APL).”

Currently, Syros scores a Strong Buy analyst consensus based on 4 unanimous Buys. The average price target stands at $16.50, reflecting upside potential of 112.6% from current levels. Shares have advanced 12.5% so far this year.

Last month, H.C. Wainwright analyst Andrew Fein upgraded Syros to Buy from Hold and raised the price target to $15 from $11. In a note to investors, Fein stated that with the SY-1365 discontinuation behind the company, it is clear that Syros has been able to learn from what that asset provided and “make a strong decision to pursue the better of the two CDK7 inhibitors with SY-5609.”

The analyst believes that the company has validated in the preclinical and clinical setting the feasibility of SY-5609 as an oral CDK7 inhibitor to potentially progress into further clinical development for solid tumor indications.

Related News:
BioCryst Pops 19% After FDA Approval Of Orladeyo Therapy; Needham Says Hold
Eli Lilly Inks $812.5M Covid-19 Antibody Supply Deal With US; Street Sees 18% Upside 
Merck Cashes In On Moderna Equity Investment As Stock Pops 631% YTD 

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More